Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 997 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inhibition Clear all
Completed Phase 3 Interventional

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

NCT03754790
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 2 Interventional

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

NCT06331624
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
Tazarotene (GRI-0621), Placebo
Drug
Lead sponsor
GRI Bio Operations, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 19, 2026, 6:39 AM EDT
Terminated Phase 2 Interventional Results available

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

NCT03002623
View directory record Official record
Conditions
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
Interventions
CUDC-907
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 2 Interventional Results available

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

NCT00396591
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 19, 2026, 6:39 AM EDT
Not yet recruiting Phase 4 Interventional

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

NCT07770646
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA)
Interventions
Secukinumab (IL-17i ), Upadacitinib (JAKi)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

NCT03515512
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions
Enasidenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 0.4% Ketorolac and Vitreoretinal Surgery

NCT00576329
View directory record Official record
Conditions
Surgery
Interventions
Ketorolac
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

NCT01378429
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
ciclesonide nasal aerosol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 19, 2026, 6:39 AM EDT
Recruiting Phase 2 Interventional

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

NCT06865339
View directory record Official record
Conditions
NSCLC, Locally Advanced
Interventions
Cemiplimab, Fianlimab, Radiotherapy, Platinum Doublet Chemotherapy (PDC)
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 6:39 AM EDT
Not yet recruiting Phase 2 Interventional

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

NCT07580339
View directory record Official record
Conditions
Rectal Cancer
Interventions
DCSZ11, Radiation, Capecitabine, Oxaliplatin
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Gevokizumab for Active Scleritis

NCT01835132
View directory record Official record
Conditions
Scleritis
Interventions
Gevokizumab
Device
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 19, 2026, 6:39 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth

NCT02569216
View directory record Official record
Conditions
Premature Birth, Premature Labor
Interventions
Electrical Inhibition (EI)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder

NCT03896516
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, GLWL-01
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sucralose and Lactisole Additions to OGTT in Humans

NCT05900193
View directory record Official record
Conditions
Neat OGTT, OGTT With Added Sucralose, OGTT With Added Lactisole
Interventions
TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 1Phase 2 Interventional

Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome

NCT00637221
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
NPL-2009
Drug
Lead sponsor
Neuropharm
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 19, 2026, 6:39 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

NCT04323189
View directory record Official record
Conditions
Genetics Disease, Type2 Diabetes, Heart Failure
Interventions
Sitagliptin 100mg, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 19, 2026, 6:39 AM EDT
Not yet recruiting Phase 1 Interventional

Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC

NCT07783659
View directory record Official record
Conditions
Phase IB, Zotatifin, EIF4A, Advanced TNBC, Platinum Helix Inhibition
Interventions
Zotatifin, carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 6:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Rapalog Pharmacology (RAP PAC) Study

NCT05949658
View directory record Official record
Conditions
Aging
Interventions
Sirolimus, Everolimus
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 89 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 19, 2026, 6:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

NCT03809234
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 19, 2026, 6:39 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

NCT05191004
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
Interventions
NUV-422, Fulvestrant
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 19, 2026, 6:39 AM EDT
Terminated Phase 1 Interventional

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

NCT04330625
View directory record Official record
Conditions
Hyperglycemia Drug Induced
Interventions
REMD-477
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 19, 2026, 6:39 AM EDT
Terminated Phase 2 Interventional Results available

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

NCT01519427
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • New Brunswick, New Jersey • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 19, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

NCT00070057
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
celecoxib, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 19, 2026, 6:39 AM EDT
Terminated Phase 1 Interventional

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

NCT01541670
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Yuba City, California • Centennial, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 19, 2026, 6:39 AM EDT